Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INSTant CARMA

Financiado

In Silico Trials for Cartilage Regenerative Medicine Applications

Osteoarthritis (OA) is a highly prevalent disease, affecting 1 in 8 adults worldwide and is projected to increase by 60% in the next two decades. Due to the intricate interplay between multiple influencing factors such as mechanic... ver más

31/08/2028

ULIEGE

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITE DE LIEGE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-08-28

ERC-2022-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

2 Participantes

ULIEGE

938.89K€ | Lider

KU Leuven

1.27M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SYNERGIES Smart bioreactor-based platform for the multi-phYsical stimu... 189K€ Cerrado

ANCHOR Articular cartilage regeneration through the recruitment of... 150K€ Cerrado

PTQ-09-02-01290 Estudio experimental y computacional del proceso de regenera... 92K€ Cerrado

SIMBIONT A data driven multiscale simulation of organogenesis 2M€ Cerrado

EQC2018-005046-P UNIDAD EXPERIMENTAL DE TERAPIA REGENERATIVA EN PATOLOGÍAS OS... 292K€ Cerrado

EIN2019-103177 INNOVACION EN INGENIERIA REGENERATIVA PARA LA INTERVENCION T... 16K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-08-28
Fecha Fin: 2028-08-31

Líder del proyecto

UNIVERSITE DE LIEGE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Osteoarthritis (OA) is a highly prevalent disease, affecting 1 in 8 adults worldwide and is projected to increase by 60% in the next two decades. Due to the intricate interplay between multiple influencing factors such as mechanical loading and inflammation playing out over multiple length scales and tissue compartments, currently no disease-modifying drugs are available on the market. The INSTAnt CARMA project aims to harness the power of in silico trials to study OA onset and progression, as well as design endogenous (drugs) and exogenous (tissue engineered) therapies. A multiscale multifactorial in silico model of the knee joint will be established and validated with dedicated in vitro and in vivo experiments. A continuous effort following targeted and untargeted approaches will take place to explore biological hypotheses and implement relevant model extensions. In parallel, computational upscaling tools will be implemented to prepare the model for execution of in silico trial simulations on virtual patient cohorts. The first in silico trial will investigate the effect of model-predicted drug combinations after experimental confirmation in a rodent model. The second trial will seek to optimize tissue engineered constructs for deep osteochondral defect regeneration, followed by experimental validation in a small and large animal model. To realize its goals, INSTAnt CARMA can build on the well-received and published work on a wide range of in silico, in vitro and in vivo tools developed by the applicant and her team. Additionally, the work will benefit from the applicant’s extensive network and involvement in regulatory science for in silico medicine. This project will further accelerate the uptake of in silico testing strategies in the development of medical therapies in general and osteoarthritis in particular.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores